| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6294540 | VIIV HLTHCARE | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
May, 2018
(5 years ago) | |
|
US6294540 (Pediatric) | VIIV HLTHCARE | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
Nov, 2018
(5 years ago) | |
| US6641843 | VIIV HLTHCARE | Pharmaceutical compositions |
Feb, 2019
(5 years ago) | |
|
US6641843 (Pediatric) | VIIV HLTHCARE | Pharmaceutical compositions |
Aug, 2019
(4 years ago) | |
Ziagen is owned by Viiv Hlthcare.
Ziagen contains Abacavir Sulfate.
Ziagen has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Ziagen are:
- US6294540
- US6294540*PED
- US6641843
- US6641843*PED
Ziagen was authorised for market use on 17 December, 1998.
Ziagen is available in tablet;oral, solution;oral dosage forms.
Ziagen can be used as method of treatment of a patient infected with hiv.
The generics of Ziagen are possible to be released after 04 August, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-147) | Mar 23, 2018 |
Drugs and Companies using ABACAVIR SULFATE ingredient
Market Authorisation Date: 17 December, 1998
Treatment: Method of treatment of a patient infected with hiv
Dosage: TABLET;ORAL; SOLUTION;ORAL
How can I launch a generic of ZIAGEN before it's drug patent expiration?
More Information on Dosage
ZIAGEN family patents
